Friday, November 21, 2025 1:32:34 PM
The key point is that SOW-8 and the new Grade C manufacturing suite are about two completely different things, and they occur on two different regulatory timelines. SOW-8 was carried out in Sawston using the existing Grade C cleanrooms that were already real, licensed, ISO-qualified, and functional well before 2024. That is documented in three independent places: the Catapult manufacturing surveys (showing 3 Grade C rooms as far back as 2023), the 2023 10-Q (Phase 1B completion with new PD lab + multiple Grade C rooms), and the SOW-8 milestone disclosures themselves (APS, PPQ, equipment qualification, all of which are legally impossible without functioning Grade C/B/A space). So yes, Sawston already has Grade C rooms and they were absolutely functioning for SOW-8.
The November PR is not announcing the first Grade C capability. It is announcing the first Grade C manufacturing suite dedicated to Eden, which is a commercial-throughput, multi-pod, high-volume block designed for scale-out? not basic regulatory readiness. NWBO is building it now because Eden is close to regulatory comparability and because they expect commercial demand. You do not wait for the next 10-Q to announce a major construction project that more than doubles capacity; you disclose it immediately, just like they did with Phase 1A and 1B. It is a sign of expansion, not a sign of missing infrastructure.
So to your concern: No, this does not delay approval. The existing, licensed Grade C cleanrooms are already operational and were already used for SOW-8, which is the regulatory prerequisite for DCVax manufacturing readiness. The new suite is simply a larger, Eden-optimized commercial unit that will take throughput from “functional” to “high-capacity.” It’s the difference between “we can manufacture” and “we can manufacture at scale.” The PR is about the latter, not the former, and it does not imply that NWBO must wait six months for a Grade C environment to exist. It already exists.
Finally, Beartrap is correct: the Catapult 2023 report confirms that Advent already had 3 Grade C cleanrooms inside Phase 1B years ago. That matches all the independent documentation, and fully explains how SOW-8 was completed at Sawston.
The November PR is not announcing the first Grade C capability. It is announcing the first Grade C manufacturing suite dedicated to Eden, which is a commercial-throughput, multi-pod, high-volume block designed for scale-out? not basic regulatory readiness. NWBO is building it now because Eden is close to regulatory comparability and because they expect commercial demand. You do not wait for the next 10-Q to announce a major construction project that more than doubles capacity; you disclose it immediately, just like they did with Phase 1A and 1B. It is a sign of expansion, not a sign of missing infrastructure.
So to your concern: No, this does not delay approval. The existing, licensed Grade C cleanrooms are already operational and were already used for SOW-8, which is the regulatory prerequisite for DCVax manufacturing readiness. The new suite is simply a larger, Eden-optimized commercial unit that will take throughput from “functional” to “high-capacity.” It’s the difference between “we can manufacture” and “we can manufacture at scale.” The PR is about the latter, not the former, and it does not imply that NWBO must wait six months for a Grade C environment to exist. It already exists.
Finally, Beartrap is correct: the Catapult 2023 report confirms that Advent already had 3 Grade C cleanrooms inside Phase 1B years ago. That matches all the independent documentation, and fully explains how SOW-8 was completed at Sawston.
Bullish
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
